stockrow
Friday 6 November 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.01
−2.17%
Follow GELS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Dec ’25 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | — | (4.1%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 92.12 | 92.10 | 100.00 | 79.73 | — | (12.4) pt | ||||||
| EBT | — | — | — | — | — | — | (2) | (2) | (2) | (4) | — | +22.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | (565.09) | (565.09) | (2,414.95) | (1,167.87) | — | (602.8) pt | ||||||
| Net income | — | — | — | — | — | — | 0 | (2) | (2) | (4) | (2) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.05 | 0.01 | 0.04 | — | n/m | |||||
| Earnings | — | — | — | — | — | — | — | (0.30) | (0.29) | (0.47) | — | +25.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | (0.15) | (0.09) | (0.39) | 0.00 | +60.3% | ||||||
| Capex | — | — | — | — | — | — | — | (0.01) | (0.01) | (0.04) | 0.00 | +164.9% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (0.16) | (0.10) | (0.43) | 0.00 | +65.9% | ||||||
| Book value | — | — | — | — | — | — | 0.00 | 1.58 | 1.22 | 1.10 | 0.00 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | 8 | 8 | 9 | — | +8.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.38) | (0.49) | (0.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (4) | (7) | +73.2% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | +185.3% | ||||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (4) | (7) | +79.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 0 | 0 | (2) | (3) | (4) | +119.8% | |||||
| Net debt | — | — | — | — | — | — | 1 | 1 | 3 | 3 | 3 | +21.6% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 13 | 13 | 10 | 10 | 9 | (6.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (15.59) | (15.59) | (16.17) | (31.28) | 0.00 | (15.7) pt | |||||
| ROIC | — | — | — | — | — | — | (9.35) | (9.35) | (9.73) | (17.46) | 0.00 | (8.1) pt | ||||||
| ROE | — | — | — | — | — | — | 44.10 | (65.48) | (20.70) | (42.72) | 0.00 | (86.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 8 | 8 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.05 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2025 · fundamentals updated 25 Oct 2026
Gelteq Limited vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INM InMed Pharmaceuticals Inc. | $7.3M | — (loss-making) | — | −26.22% (below 0%: shrinking) | n/m | +40.84% (above 0%: growing) | 22.46% | 0.00% | Compare |
| UPC Universe Pharmaceuticals INC | $7.0M | — (loss-making) | 4.1× | −23.98% (below 0%: shrinking) | −110.15% (below 0%: shrinking) | −84.99% (below 0%: shrinking) | 32.57% | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.1M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.9M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | |
| YCBD cbdMD, Inc. | $4.4M | — (loss-making) | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.1M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| RDHL Redhill Biopharma Ltd. | $3.8M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| PRFX PainReform Ltd. | $2.3M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AKAN Akanda Corp. | $2.2M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | Compare |
| Median of peers | $4.2M | — | — | −23.98% | — | −16.57% | 22.46% | 0.00% |